PMID- 31346147
OWN - NLM
STAT- MEDLINE
DCOM- 20190807
LR  - 20190807
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 71
IP  - 8
DP  - 2019 Aug
TI  - [Efficacy and Safety of Lorazepam Intravenously Administered in Subjects with 
      Status Epilepticus or Repetitive Seizures].
PG  - 901-910
LID - 10.11477/mf.1416201373 [doi]
AB  - We evaluated the efficacy and safety of lorazepam (LZP) 4 mg for adults (age, 16 
      years old or older) or 0.05mg/kg for children (age, 3 months to less than 16 
      years) as a slow intravenous injection in 26 Japanese patients with status 
      epilepticus or repetitive seizures. The proportion of patients whose initial 
      seizure stopped within 10 minutes and who continued seizure-free for at least 30 
      minutes after the completion of initial dose as the primary endpoint was 48.0% 
      (12/25, 95%CI: 27.8%-68.7%). However, the proportion of patients whose seizures 
      stopped within 10 minutes and who continued seizure-free for at least 30 minutes 
      after the completion of either initial or second dose (in 10 to 30 minutes from 
      the initial dose) was 64.0% (16/25, 95%CI: 42.5%-82.0%) in total, and 77.8% and 
      56.3% in adults and children, respectively. The most common adverse events (AEs) 
      were somnolence (7.7%) and insomnia (7.7%), and almost all AEs were mild or 
      moderate in severity. No patient experienced serious or severe LZP-related AEs. 
      No one discontinued the study due to AEs.
FAU - Ohtsuka, Yoko
AU  - Ohtsuka Y
AD  - Asahigawaso Rehabilitation and Medical Center.
FAU - Nakasato, Nobukazu
AU  - Nakasato N
FAU - Nakazuru, Yoshiomi
AU  - Nakazuru Y
FAU - Terada, Michinori
AU  - Terada M
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
RN  - 0 (Anticonvulsants)
RN  - O26FZP769L (Lorazepam)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Injections, Intravenous
MH  - Lorazepam/adverse effects/*therapeutic use
MH  - Seizures/*drug therapy
MH  - Status Epilepticus/*drug therapy
EDAT- 2019/07/28 06:00
MHDA- 2019/08/08 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/07/27 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2019/08/08 06:00 [medline]
AID - 1416201373 [pii]
AID - 10.11477/mf.1416201373 [doi]
PST - ppublish
SO  - Brain Nerve. 2019 Aug;71(8):901-910. doi: 10.11477/mf.1416201373.